Patrícia Silva, PhD,  director of science content—

Patrícia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. Patrícia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by Patrícia Silva

Corbus to Reveal Promising Data on Experimental CF Therapy Resunab

Corbus Pharmaceuticals Holdings, Inc., a company focused on the development and commercialization of new therapies for rare, chronic, serious inflammatory and fibrotic diseases, recently announced that its President and Chief Scientific Officer Dr. Mark A. Tepper is presenting a poster (June 1-2) at the 2015 Cystic Fibrosis Foundation Research…

Parion Sciences Awarded Best Late Stage Product Development Company

The Best Late Stage Product Development Company Award was recently granted to Parion Sciences by the Triangle Business Journal and accounting firm BDO. The company, which is focused on creating novel therapies for both pulmonary and ocular medical conditions, was presented with the award at an event in Cary, North Carolina, and is part of the third-annual…

La Jolla Pharmaceutical Acquires Rights To Gentamicin Derivatives For Cystic Fibrosis Treatment

In a recent agreement with the Indiana University Research and Technology Corp. (IURTC), La Jolla Pharmaceutical Co. acquired intellectual property rights covering next-generation derivatives of gentamicin, an antibiotic used in the treatment of several types of bacterial infections, namely heart, urinary tract, and pregnancy-related infections. Gentamicin treatment is effective…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.